Treatment outcomes among children and adolescents with extensively drug-resistant (XDR) and pre-XDR tuberculosis: Systematic review and meta-analysis.
Extensively drug-resistant (XDR) and pre-XDR- tuberculosis (TB) account for approximately a third of pediatric MDR-TB cases globally. Clinical management is challenging; recommendations are based on limited evidence. We assessed the clinical outcomes for children and adolescents treated for XDR-and...
Saved in:
Main Authors: | , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2025-01-01
|
Series: | PLOS Global Public Health |
Online Access: | https://doi.org/10.1371/journal.pgph.0003754 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
_version_ | 1825206725054038016 |
---|---|
author | Jayadeep Patra Hyacinth Irving Pranshu Maini Jady Liang Anwesh Patra Mandar Paradkar Jurgen Rehm |
author_facet | Jayadeep Patra Hyacinth Irving Pranshu Maini Jady Liang Anwesh Patra Mandar Paradkar Jurgen Rehm |
author_sort | Jayadeep Patra |
collection | DOAJ |
description | Extensively drug-resistant (XDR) and pre-XDR- tuberculosis (TB) account for approximately a third of pediatric MDR-TB cases globally. Clinical management is challenging; recommendations are based on limited evidence. We assessed the clinical outcomes for children and adolescents treated for XDR-and pre-XDR-TB. We performed a systematic review and meta-analysis of published studies reporting treatment outcomes for children and adolescents with XDR-and pre-XDR-TB. MEDLINE, EMBASE, Scopus, Web of Science, Google Scholar, and trial registries up to 31 December 2023 were searched. Eligible studies included children and adolescents aged <18 years with XDR-or pre-XDR-TB. The primary outcome was treatment success, defined as a composite of cure and treatment completion. Secondary outcomes were death, failure/ lost to follow-up and adverse events. We identified 34 population-based studies and 14 case studies, which reported treatment outcomes for a total of 656 patients. Treatment durations ranged from 6 to 27 months; follow-up after treatment completion ranged from 2 months to 4 years. The pooled estimate for treatment success in XDR-and pre-XDR-TB was 88·9% (95%CI: 59·7-100%) and 65·4% (95%CI: 27·7-100%), respectively. Drug adverse effects were reported in 56.4% (95%CI: 9.9-100%) and 68.2% (95%CI: 0-100%) of children respectively. Few childhood XDR- and pre-XDR-TB cases are reported. The relatively good treatment outcomes in children compared to adults may be partly due to publishing bias. Drug adverse effects are common. |
format | Article |
id | doaj-art-80ecb273f6e34c1cb22807ebdee32a00 |
institution | Kabale University |
issn | 2767-3375 |
language | English |
publishDate | 2025-01-01 |
publisher | Public Library of Science (PLoS) |
record_format | Article |
series | PLOS Global Public Health |
spelling | doaj-art-80ecb273f6e34c1cb22807ebdee32a002025-02-07T05:48:13ZengPublic Library of Science (PLoS)PLOS Global Public Health2767-33752025-01-0151e000375410.1371/journal.pgph.0003754Treatment outcomes among children and adolescents with extensively drug-resistant (XDR) and pre-XDR tuberculosis: Systematic review and meta-analysis.Jayadeep PatraHyacinth IrvingPranshu MainiJady LiangAnwesh PatraMandar ParadkarJurgen RehmExtensively drug-resistant (XDR) and pre-XDR- tuberculosis (TB) account for approximately a third of pediatric MDR-TB cases globally. Clinical management is challenging; recommendations are based on limited evidence. We assessed the clinical outcomes for children and adolescents treated for XDR-and pre-XDR-TB. We performed a systematic review and meta-analysis of published studies reporting treatment outcomes for children and adolescents with XDR-and pre-XDR-TB. MEDLINE, EMBASE, Scopus, Web of Science, Google Scholar, and trial registries up to 31 December 2023 were searched. Eligible studies included children and adolescents aged <18 years with XDR-or pre-XDR-TB. The primary outcome was treatment success, defined as a composite of cure and treatment completion. Secondary outcomes were death, failure/ lost to follow-up and adverse events. We identified 34 population-based studies and 14 case studies, which reported treatment outcomes for a total of 656 patients. Treatment durations ranged from 6 to 27 months; follow-up after treatment completion ranged from 2 months to 4 years. The pooled estimate for treatment success in XDR-and pre-XDR-TB was 88·9% (95%CI: 59·7-100%) and 65·4% (95%CI: 27·7-100%), respectively. Drug adverse effects were reported in 56.4% (95%CI: 9.9-100%) and 68.2% (95%CI: 0-100%) of children respectively. Few childhood XDR- and pre-XDR-TB cases are reported. The relatively good treatment outcomes in children compared to adults may be partly due to publishing bias. Drug adverse effects are common.https://doi.org/10.1371/journal.pgph.0003754 |
spellingShingle | Jayadeep Patra Hyacinth Irving Pranshu Maini Jady Liang Anwesh Patra Mandar Paradkar Jurgen Rehm Treatment outcomes among children and adolescents with extensively drug-resistant (XDR) and pre-XDR tuberculosis: Systematic review and meta-analysis. PLOS Global Public Health |
title | Treatment outcomes among children and adolescents with extensively drug-resistant (XDR) and pre-XDR tuberculosis: Systematic review and meta-analysis. |
title_full | Treatment outcomes among children and adolescents with extensively drug-resistant (XDR) and pre-XDR tuberculosis: Systematic review and meta-analysis. |
title_fullStr | Treatment outcomes among children and adolescents with extensively drug-resistant (XDR) and pre-XDR tuberculosis: Systematic review and meta-analysis. |
title_full_unstemmed | Treatment outcomes among children and adolescents with extensively drug-resistant (XDR) and pre-XDR tuberculosis: Systematic review and meta-analysis. |
title_short | Treatment outcomes among children and adolescents with extensively drug-resistant (XDR) and pre-XDR tuberculosis: Systematic review and meta-analysis. |
title_sort | treatment outcomes among children and adolescents with extensively drug resistant xdr and pre xdr tuberculosis systematic review and meta analysis |
url | https://doi.org/10.1371/journal.pgph.0003754 |
work_keys_str_mv | AT jayadeeppatra treatmentoutcomesamongchildrenandadolescentswithextensivelydrugresistantxdrandprexdrtuberculosissystematicreviewandmetaanalysis AT hyacinthirving treatmentoutcomesamongchildrenandadolescentswithextensivelydrugresistantxdrandprexdrtuberculosissystematicreviewandmetaanalysis AT pranshumaini treatmentoutcomesamongchildrenandadolescentswithextensivelydrugresistantxdrandprexdrtuberculosissystematicreviewandmetaanalysis AT jadyliang treatmentoutcomesamongchildrenandadolescentswithextensivelydrugresistantxdrandprexdrtuberculosissystematicreviewandmetaanalysis AT anweshpatra treatmentoutcomesamongchildrenandadolescentswithextensivelydrugresistantxdrandprexdrtuberculosissystematicreviewandmetaanalysis AT mandarparadkar treatmentoutcomesamongchildrenandadolescentswithextensivelydrugresistantxdrandprexdrtuberculosissystematicreviewandmetaanalysis AT jurgenrehm treatmentoutcomesamongchildrenandadolescentswithextensivelydrugresistantxdrandprexdrtuberculosissystematicreviewandmetaanalysis |